DBVT Stock Analysis: DBV Technologies | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 936m USD | 12M Return: 57.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.33M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DBV Technologies S.A. (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, founded in 2002 and listed on NASDAQ since 2014. The company specializes in epicutaneous immunotherapy, a non-invasive delivery approach that administers allergens through the skin via a patch, distinguishing it from traditional oral or subcutaneous immunotherapy methods. Its lead candidate, Viaskin Peanut, has completed Phase 3 clinical trials for peanut allergy treatment, while Viaskin Milk is in Phase 1/2 development for cows milk protein allergy. Earlier-stage research targets celiac disease, and the company is leveraging its broader Viaskin technology platform across multiple food allergy indications.
As a pre-revenue, clinical-stage biotech, DBV relies on capital markets and partnerships rather than product sales to fund operations. It maintains a collaboration with Nestlé Health Science to develop MAG1C, a diagnostic atopy patch test for non-IgE mediated cows milk protein allergy in infants and toddlers. The company operates within the GICS Biotechnology sub-industry, a sector characterized by binary outcomes tied to clinical trial results and regulatory approvals.
- Viaskin Peanut FDA approval decision drives near-term valuation
- Phase 3 trial resubmission progress gates commercial launch timeline
- Cash burn and financing risk threaten pipeline development runway
- Nestlé MAG1C partnership advances atopy patch test diagnostic program
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 122.0 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -150.6m > Net Income -167.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.7m) vs 12m ago -10.93% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 5.43%; Δ -5.43% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 246.7m - Total Current Liabilities 51.8m) / Total Assets 266.4m |
| B: -1.65 (Retained Earnings -440.7m / Total Assets 266.4m) |
| C: -1.08 (EBIT TTM -171.8m / Avg Total Assets 158.5m) |
| D: 3.55 (Book Value of Equity 207.9m / Total Liabilities 58.5m) |
| Altman-Z'' = -4.15 = D |
As of July 08, 2026, the stock is trading at USD 17.35 with a total of 366,103 shares traded. Over the past week, the price has changed by +8.44%, over one month by +8.44%, over three months by -15.16% and over the past year by +57.58%.
Current recommended Stop Loss: 15.90 (which is 8.4% or 1.4 ATR below the current price).
DBV Technologies has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold DBVT.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 40.8 | 135.3% |
P/S = 163.238
P/B = 4.4931
Revenue TTM = 0.0 USD
EBIT TTM = -171.8m USD
EBITDA TTM = -159.5m USD
Long Term Debt = 5.10m USD (estimated: total debt 16.3m - short term 11.2m)
Short Term Debt = 11.2m USD (from shortTermDebt, last quarter)
Debt = 22.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.10m
Net Debt = -206.8m USD (calculated: Debt 22.4m - CCE 229.2m)
Enterprise Value = 729.5m USD (936.3m + Debt 22.4m - CCE 229.2m)
Interest Coverage Ratio = unknown (Ebit TTM -171.8m / Interest Expense TTM 0.0)
EV/FCF = -4.81x (Enterprise Value 729.5m / FCF TTM -151.5m)
FCF Yield = -20.77% (FCF TTM -151.5m / Enterprise Value 729.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 17.4m) / Revenue TTM)
Tobins Q-Ratio = 2.74 (Enterprise Value 729.5m / Total Assets 266.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 22.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -135.8m (EBIT -171.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.76 (Total Current Assets 246.7m / Total Current Liabilities 51.8m)
Debt / Equity = 0.11 (Debt 22.4m / totalStockholderEquity, last quarter 207.9m)
Debt / EBITDA = 1.30 (negative EBITDA) (Net Debt -206.8m / EBITDA -159.5m)
Debt / FCF = 1.36 (negative FCF - burning cash) (Net Debt -206.8m / FCF TTM -151.5m)
Total Stockholder Equity = 128.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -105.9% (out of range, set to none)
RoE = -130.2% (Net Income TTM -167.8m / Total Stockholder Equity 128.9m)
RoCE = -128.2% (out of range, set to none) (EBIT -171.8m / Capital Employed (Equity 128.9m + L.T.Debt 5.10m))
RoIC = -60.12% (negative operating profit) (NOPAT -135.8m / Invested Capital 225.8m)
WACC = 12.32% (E(936.3m)/V(958.7m) * Re(12.61%) + D(22.4m)/V(958.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.49 | Cagr: -4.97%
[DCF] Fair Price = unknown (Cash Flow -151.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.07 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.45 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=-3.31% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.13 | Chg30d=-3.03% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.46 | Chg30d=-2.02% | Revisions=+0% | GrowthEPS=+50.0% | GrowthRev=-23.4%
EPS next Year (2027-12-31): EPS=-0.43 | Chg30d=-3.03% | Revisions=+0% | GrowthEPS=+5.1% | GrowthRev=+2036.6%
[Analyst] Revisions Ratio: -22% (up=2, down=4)